Next-Generation ‘Rocker’ Bioreactor is Ideal for Suspension Cultures
for Life Sciences Applications Up to Full GMP Production
PORT WASHINGTON, N.Y., March 22, 2013 -
Pall Corporation (NYSE:PLL),
a global leader in filtration, separation and purification, today
introduced the XRS 20 Bioreactor System, a new bioreactor with unique
agitation properties that incorporates a single-use, easy-to-use
Allegro™ 3D biocontainer. This next generation ‘rocker’ bioreactor,
designed for cultivation of mammalian cells in suspension culture, is
equally suitable for applications ranging from general life sciences
research to seed train operations and full Good Manufacturing Practice
(GMP) production at the 2-to-20 liter scale.
The Pall XRS 20 Bioreactor System's unique bi-axial agitation properties improve cell culture performance. (Photo: Business Wire)
The XRS 20 System’s unique bi-axial agitation promotes better mixing and
higher mass transfer, which expedites transport of nutrients and
metabolites in the cellular micro-environment. This allows cultures to
reach higher densities with overall greater viabilities, leading to
significantly higher protein expression levels.
To ensure operational simplicity, the system includes the following
Allegro XRS 20 biocontainer with integrated components (sensors,
filters, drain and tubing sets) for rapid installation and efficient
Advanced XRS 20 controller with touchscreen interface for easy
monitoring and control of process parameters
A fully enclosed XRS 20 platform with interlock provides operator safety
while protecting sensitive media components from light.
“The versatile, easy-to-use XRS 20 Bioreactor System combines
state-of-the-art, single-use technology with advanced controls and
features that improve cell culture performance,” said Ken Frank,
President, Pall BioPharmaceuticals.
Pall Life Sciences provides cutting-edge products and services to meet
the demanding needs of customers discovering, developing and producing
biotech drugs, vaccines and classic pharmaceuticals. The company’s
membranes and membrane devices optimize detection and sample preparation
in the drug research, clinical diagnostics, genomics, and proteomics
markets. Pall is a leading provider of separation systems and single-use
filtration and purification technologies to pharmaceutical and
biotechnology companies to support faster development of new drugs and
vaccines that are safer and require less energy and water to produce.
Pall technologies are also used in clinical institutions and the food
and beverage industries.
About Pall Corporation
Pall Corporation (NYSE:PLL)
is a filtration, separation and purification leader providing solutions
to meet the critical fluid management needs of customers across the
broad spectrum of life sciences and industry. Pall works with customers
to advance health, safety and environmentally responsible technologies.
The Company’s engineered products enable process and product innovation
and minimize emissions and waste. Pall Corporation is an S&P 500 company
serving customers worldwide. Pall has been named a “top green company”
by Newsweek magazine. To see how Pall is helping enable a greener,
safer, more sustainable future, follow us on Twitter @PallCorporation
or visit www.pall.com/green.